Reported 1 day ago
Gilead Sciences, Inc. (NASDAQ:GILD) has announced that it received marketing authorization from the European Commission for Yeytuo (lenacapavir), a twice-yearly injectable HIV-1 capsid inhibitor. This drug serves as a pre-exposure prophylaxis (PrEP) for adults and adolescents at high risk for HIV-1, making it the first and only option approved for use across the 27 EU member states. Gilead continues to focus on developing medicines for critical health needs across more than 35 countries.
Source: YAHOO